Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.
Laura C. Michaelis, MD
Advertisement
Articles by Laura C. Michaelis, MD
Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.
Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.
Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.
Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.
Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Michaelis on Treating Patients With Myelofibrosis and AnemiaFebruary 21st 2020
Dr. Michaelis on the Role of Interferon in MPNsMay 4th 2020
Dr. Michaelis on Fedratinib in Myelofibrosis TreatmentSeptember 12th 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer
5